News

November 2016 Newsletter

With the recent presentation of the data from Keynote-024, and the recent approval of pembrolizumab for high PD-L1 expressing tumors, the landscape of lung cancer oncology will change dramatically and for the better.

DENVER – Under the leadership of the International Association for the Study of Lung Cancer (IASLC), a consortium of lung cancer patient advocacy organizations and individuals have come together to develop a harmonized public awareness campaign for November’s annual Lung Cancer Awareness Month (LCAM).

DENVER – Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection.

October 2016 Newsletter

Your IASLC has just partnered with the Chinese Society of Clinical Oncology (CSCO), chaired by IASLC Board of Directors member Yi-Long Wu, to present a joint IASLC-CSCO symposium.

DENVER – The timing of surgery after neoadjuvant chemoradiation in patients with stage IIIA non-small cell lung cancer (NSCLC) affects the overall survival of patients receiving trimodality therapy.

DENVER – Malignant mesothelioma is a form of cancer that invades the lining of the lung or chest cavity and is often caused by exposure to carcinogenic mineral fibers such as asbestos and erionite (a natural mineral found in volcanic ash). The International Association for the Study of Lung Cancer (IASLC) is joining other organizations in support of Mesothelioma Awareness Day on September 26 to raise greater public awareness for this disease.

Pages